专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08685460B2 Treatment using dantrolene 有权
标题翻译：使用丹曲林治疗
公开(公告)号：US08685460B2
公开(公告)日：2014-04-01
申请号：US13353478
申请日：2012-01-19
申请人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K9/16 , A61K31/415 , A61K9/00 , A61K9/10 , A61K31/4166 , C07D233/80
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

2. 发明申请

US20080145434A1 COMPOSITIONS FOR THE REVERSAL AND DETOXIFICATION OF ANESTHETICS AND OTHER COMPOUNDS AND METHODS OF THEIR USE 有权
标题翻译：麻醉剂和其他化合物的反转和脱氧作用的组合物及其使用方法
公开(公告)号：US20080145434A1
公开(公告)日：2008-06-19
申请号：US11951847
申请日：2007-12-06
申请人： David M. Anderson , Vincent M. Conklin , Benjamin G. Cameransi
发明人： David M. Anderson , Vincent M. Conklin , Benjamin G. Cameransi
IPC分类号： A61K9/14 , A61K31/05 , A61K31/4164 , A61K31/135 , A61K31/505 , A61K31/445 , A61K31/045 , A61K31/235 , A61K31/01 , A61K31/355 , A61K31/451 , A61K31/4439 , A61K31/167 , A61K31/46
CPC分类号： A61K31/01 , A61K9/0019 , A61K9/1274 , A61K31/045 , A61K31/05 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/235 , A61K31/355 , A61K31/4164 , A61K31/4439 , A61K31/445 , A61K31/451 , A61K31/46 , A61K31/505
摘要： Methods of attenuating the toxic or medically undesirable effects of drugs and toxins in a human by administering to a human an injectable formulation comprised of a dispersion of particles comprised of reversed cubic or reversed hexagonal lyotropic liquid crystalline material. The particles absorb or adsorb or otherwise sequester and attenuate the effect of drugs and toxins, and may be used as a rescue or reversal agent, or as a prophylaxis. The invention is especially applicable in reversing adverse effects of local anesthetics inadvertently delivered systemically, and attenuating the therapeutic effects of general anesthetics in the course of treatment.
摘要翻译：通过向人施用包含由反相立方或反六六位溶致液晶材料构成的颗粒分散体的可注射制剂来减弱药物和毒素在人体中的毒性或医学上不良影响的方法。颗粒吸收或吸附或以其它方式螯合和减弱药物和毒素的作用，并且可以用作救援或逆转剂或作为预防。本发明特别适用于系统地无意地递送局部麻醉药物的不良反应，并减轻治疗过程中全身麻醉药物的治疗效果。

3. 发明申请

US20120121663A1 TREATMENT USING DANTROLENE 有权
标题翻译：使用DANTROLENE治疗
公开(公告)号：US20120121663A1
公开(公告)日：2012-05-17
申请号：US13353480
申请日：2012-01-19
申请人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
发明人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/10 , A61P43/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

4. 发明申请

US20100160400A1 TREATMENT USING DANTROLENE 有权
标题翻译：使用DANTROLENE治疗
公开(公告)号：US20100160400A1
公开(公告)日：2010-06-24
申请号：US12717588
申请日：2010-03-04
申请人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
发明人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61P23/00 , A61P9/00 , A61P21/02 , A61P25/28
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

5. 发明授权

US08604072B2 Treatment using dantrolene 有权
标题翻译：使用丹曲林治疗
公开(公告)号：US08604072B2
公开(公告)日：2013-12-10
申请号：US13353480
申请日：2012-01-19
申请人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K31/415 , A61K9/14 , A61K9/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

6. 发明申请

US20120121662A1 TREATMENT USING DANTROLENE 有权
公开(公告)号：US20120121662A1
公开(公告)日：2012-05-17
申请号：US13353478
申请日：2012-01-19
申请人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
发明人： David Anderson , Benjamin G. Cameransi, JR. , Vincent M. Conklin
IPC分类号： A61K31/4178 , A61K9/10 , A61P43/00
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

7. 发明授权

US08110225B2 Treatment using dantrolene 有权
标题翻译：使用丹曲林治疗
公开(公告)号：US08110225B2
公开(公告)日：2012-02-07
申请号：US12717588
申请日：2010-03-04
申请人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K9/14 , A61K9/00 , A61K31/415
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：提供的低容量，安非他酮注射剂配方，与目前批准和销售的用于恶性高热（MH）威胁性麻醉危机的丹曲林相比，具有显着的优势。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。丹那罗林注射剂配方的体积小，安全性高于目前使用的泵头预防和治疗方法，以及其他神经系统，认知功能障碍和运动功能障碍对医源性或创伤引起的血流变化情况的影响，包括外科手术涉及CPB或相关程序的程序，以及在非正常体温发作期间由医源性或疾病引起的程序。

8. 发明授权

US07968124B2 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use 有权
标题翻译：用于麻醉剂和其他化合物的逆转和解毒的组合物及其使用方法
公开(公告)号：US07968124B2
公开(公告)日：2011-06-28
申请号：US11951847
申请日：2007-12-06
申请人： David M. Anderson , Vincent M. Conklin , Benjamin G. Cameransi
发明人： David M. Anderson , Vincent M. Conklin , Benjamin G. Cameransi
IPC分类号： A61K9/14 , A61K31/05 , A61K31/4164 , A61K31/135 , A61K31/505 , A61K31/445 , A61K31/045 , A61K31/235
CPC分类号： A61K31/01 , A61K9/0019 , A61K9/1274 , A61K31/045 , A61K31/05 , A61K31/135 , A61K31/137 , A61K31/167 , A61K31/235 , A61K31/355 , A61K31/4164 , A61K31/4439 , A61K31/445 , A61K31/451 , A61K31/46 , A61K31/505
摘要： Methods of attenuating the toxic or medically undesirable effects of drugs and toxins in a human by administering to a human an injectable formulation comprised of a dispersion of particles comprised of reversed cubic or reversed hexagonal lyotropic liquid crystalline material. The particles absorb or adsorb or otherwise sequester and attenuate the effect of drugs and toxins, and may be used as a rescue or reversal agent, or as a prophylaxis. The invention is especially applicable in reversing adverse effects of local anesthetics inadvertently delivered systemically, and attenuating the therapeutic effects of general anesthetics in the course of treatment.
摘要翻译：通过向人施用包含由反相立方或反六六位溶致液晶材料构成的颗粒分散体的可注射制剂来减弱药物和毒素在人体中的毒性或医学上不良影响的方法。颗粒吸收或吸附或以其它方式螯合和减弱药物和毒素的作用，并且可以用作救援或逆转剂或作为预防。本发明特别适用于系统地无意地递送局部麻醉药物的不良反应，并减轻治疗过程中全身麻醉药物的治疗效果。

9. 发明授权

US07758890B2 Treatment using dantrolene 有权
标题翻译：使用丹曲林治疗
公开(公告)号：US07758890B2
公开(公告)日：2010-07-20
申请号：US10788413
申请日：2004-03-01
申请人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
发明人： David Anderson , Benjamin G. Cameransi, Jr. , Vincent M. Conklin
IPC分类号： A61K9/14 , A61K9/00 , A61K31/415
CPC分类号： A61K31/4178 , A61K9/0019 , A61K9/10 , A61K9/1274 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/19 , A61K31/4166 , A61K47/10 , A61K47/18 , C07D233/80
摘要： Low volume safe for injection formulations of dantrolene yield significant advantages over the currently approved and marketed dantrolene for MH threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. Additionally, a safe for injection low volume formulation of dantrolene can be made widely available to non-anesthesiologist practitioners who have occasion to use dantrolene intravenously in the treatment of other potentially life threatening conditions, including in the field. The low volume, safe for injection formulations of dantrolene, as well as other formulations of dantrolene, have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
摘要翻译：低剂量安非他酮注射剂配方，与目前批准和上市的丹曲林相比，具有威胁麻醉危险的MH。一旦丹培罗林可以立即提供给触发MH的患者立即使用，麻醉师将能够专注于在这个复杂而不断演变的危机中对患者生理状况的管理，而不是在救援人员的费力和耗时的重组过程中。另外，可以广泛使用非麻醉医师从事静脉内使用丹曲罗治疗其他潜在危及生命的疾病，包括在现场的非麻醉医师。对于预防和治疗泵头以及其他神经系统，认知和运动功能障碍，医源性或创伤性诱发的情况，丹那罗林的低体积，安全注射剂型以及其他丹曲林制剂具有显着优点。改变的血液流量，包括涉及CPB或相关手术的手术过程中发生的血流量以及在医源性或疾病引起的非正常体温发作期间发生的血流量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式